Corvus Pharmaceuticals, Inc.
General ticker "CRVS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Corvus Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 17.8%.
Estimated limits based on current volatility of 2.9%: low 12.57$, high 13.31$
Factors to consider:
- Total employees count: 37 (+19.4%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operating losses, Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Market competition
- Current price 35.4% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.69$, 9.57$]
- 2026-12-31 to 2027-12-31 estimated range: [4.03$, 8.49$]
Financial Metrics affecting the CRVS estimates:
- Positive: with PPE of -15.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Shareholder equity ratio, % of 86.06 > 81.92
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating income (median)
Short-term CRVS quotes
Long-term CRVS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $23.41MM | $27.55MM | $42.97MM |
| Operating Income | $-23.41MM | $-27.55MM | $-42.97MM |
| Non-Operating Income | $-3.62MM | $-34.74MM | $29.65MM |
| R&D Expense | $16.53MM | $19.39MM | $33.72MM |
| Income(Loss) | $-27.03MM | $-62.29MM | $-13.32MM |
| Other Income(Loss) | $-5.28MM | $-3.20MM | $-1.96MM |
| Net Income(Loss)* | $-27.03MM | $-62.29MM | $-15.28MM |
| Stockholders Equity | $38.68MM | $32.57MM | $61.20MM |
| Assets | $45.55MM | $68.91MM | $71.12MM |
| Operating Cash Flow | $-23.93MM | $-25.42MM | $-32.80MM |
| Capital expenditure | $0.03MM | $0.00MM | $0.17MM |
| Investing Cash Flow | $15.54MM | $-27.48MM | $-7.80MM |
| Financing Cash Flow | $7.86MM | $49.03MM | $36.43MM |
| Earnings Per Share** | $-0.56 | $-1.02 | $-0.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.